2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy
Published: May 08, 2024
- Hypertrophic Cardiomyopathy (HCM) remains a common genetic heart disease in populations throughout the world.
- The prevalence of unexplained asymptomatic hypertrophy in young adults in the United States has been reported at about 1:500. Symptomatic hypertrophy based on medical claims data has been estimated at <1:3000 adults in the United States.
- This guideline updates the 2020 HCM Guideline with several revised and new recommendations for the diagnosis and treatment of HCM.
Video: 2024 Guideline for the Management of Hypertrophic Cardiomyopathy
Writing Committee Chair Steve R. Ommen, MD, FACC, FAHA and Vice Chair Carolyn Ho, MD, FAHA discuss the 2024 updates to the Hypertrophic Cardiomyopathy (HCM) Guidelines. Following FDA approval of the first cardiac myosin inhibitor mavacamten for symptomatic obstructive HCM, the guideline now includes it as an option before more invasive therapies when first-line treatments like beta blockers or calcium channel blockers are not effective. Additionally, changes in recommendations regarding exercise and activity levels are discussed, emphasizing a more inclusive approach towards physical activity for patients with HCM.
Slide Sets
- AHA Clinical Update: 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic Cardiomyopathy Slide Set
Download AHA Clinical Update Slide Set (PPTX) - 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for HCM Slide Set
Download 2024 AHA Guideline Slide Set (PDF)
